Database : HANSEN Search on : RECIDIVA/PREV [Subject descriptor] References found : 5 [refine] Displaying: 1 .. 5   in format [Detailed]

page 1 de 1

1 / 5

HANSEN

select to print

Id: 18384 Author: Biswas, S; Mondal, K. K Title: Multidrug therapy in leprosy can prevent relapse- a retrospective study ..- Source: s.l; s.n; 2002. 6 p. . Abstract: A retrospective study was done at the Leprosy Control Unit (LCU) in Durgapur of Burdwan district, West Bengal, to determine the relapse rate following multidrug therapy (MDT). A total of 1581 patients (1276 PB and 305 MB) completed MDT regimens during a period of 5 years as per WHO recommendations and National Leprosy Eradication Programme (NLEP) guidelines. The treated patients were kept under surveillance as per NLEP guidelines and searched for relapses. The results of MDT were compared with those of pre-MDT (monotherapy) era at the same centre (total: 405 patients; PB-373, MB-32) andalso with those of the Leprosy Clinic in Gopalpur (only dapsone was given to a total of 189 patients, PB-167, MB-22) Following monotherapy, the relapse rate was 10.06% at the Gopalpur Leprosy Clinic and 12.4% at the Dargapur LCU during the 2 years (PB) and 5 years (MB) of surveillance, whereas following MDT no relapse case was encountered both in PB and MB cases during the surveillance periods recommended by WHO. The results of this study are comparable with those of ohter studies. Though a few studies showed relapses during long-term surveillance beyond the periods recommended by WHO, it is once again established that MDT can prevent relapse in leprosy (AU). Descriptors: HANSENIASE/quimioter HANSENIASE/epidemiol HANSENIASE/prev RECIDIVA/prev - HANSENOSTATICOS/admin  HANSENOSTATICOS/hist  HANSENOSTATICOS/normas  HANSENOSTATICOS/uso terap  CLOFAZIMINA/uso terap  DAPSONA/uso terap  RIFAMPINA/uso terap Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 09310/s

2 / 5

HANSEN

select to print Texto Completo

Id: 18339 Author: Fleury, Raul Negrão. Title: Relapses in leprosy. Source: Hansen. int;31(1):[4-6], 2006. . Descriptors: HANSENIASE/diag HANSENIASE/microbiol HANSENIASE/patol RECIDIVA/prev Limits: ESTUDO COMPARATIVO Electronic Medium: Internet Location: BR191.1

3 / 5

HANSEN

select to print Texto Completo

Id: 18338 Author: Fleury, Raul Negrão. Title: Recidivas em hanseníase / Relapses in leprosy Source: Hansen. int;31(1):1-3, 2006. . Descriptors: HANSENIASE/diag HANSENIASE/microbiol HANSENIASE/patol RECIDIVA/prev Limits: ESTUDO COMPARATIVO Electronic Medium: Internet Location: BR191.1

4 / 5

HANSEN

select to print

Id: 14332 Author: Shetty, V. P; Wakade, A. V; Antia, N. H; Pai, V. V; Revencker, C. R; Ganapati, R; Bulchand, H. O. Title: Investigación clínica, histopatológica y bacteriológica en 2 casos de recidivas al finalizar tratamiento ROM. Source: Fontilles - Revista de Leprología;23(2):171-175, May.-Ago. 2001. . Descriptors: HANSENIASE HANSENIASE/quimioter HANSENIASE/microbiol HANSENIASE/patol RECIDIVA/prev RECIDIVA Electronic Medium: http://www.ilsl.br Location: BR191.1

5 / 5

HANSEN

select to print

Id: 14095 Author: Girdhar, B. K; Girdhar, Anita; Kumar, Anil. Title: Recidivas en pacientes de lepra multibacilares: resultado de la duración del tratemiento. Source: Fontilles - Revista de Leprología;22(5):481-495, May.-Ago. 2000. tab, graf. Abstract: Se comparan dos grupos de pacientes MB: uno tratado hasta negatividad en frotis (TSN) y el otro con terapia de duración fija (24 dosis MB OMS) (FDT), para determinar los índices de recidivas durante el tratamiento y el período post-tratamiento, encontrando 20 recidivas (2.04/100 pacientes/año) durante el seguimiento de 980.2 personas/año en 260 pacientes tratados en FDT. En el otro grupo , 301 pacientes recibieron tratamiento hasta negativización, detectándose 12 recidivas en 1085.46 personas/año (1.10/100 pacientes año). La comparación de los índices de supervivencia (sin recidivas) revela que aunque no hay diferencia significativa hasta los 4 años, el riesgo de recidiva es significativamente mayor en el grupo FDT durante un período mayor de seguimiento. Además, cuando se compara en los pacientes la carga bacilar inicial, se observa un índice de recidivas mayor en el grupo con IB≥4, significativamente mayor (p<0.01) que en el grupo FDT comparado con el grupo que recibe tratamiento hasta la completa negativización del frotis (4.29 años 1.27/100 pacientes/años). Todos los pacientes con recidivas respondieron al tratamiento con la misma combinación de medicamentos, indicando qu la exacerbación de su condición es por insuficiente tratamiento. Se sugiere para prevenir o reducir recidivas, el continuar cuando sea posible el tratamiento hasta negativización del frotis, al menos en pacientes con IB elevado. (AU). Descriptors: HANSENIASE/quimioter HANSENIASE/prev RECIDIVA/prev Electronic Medium: http://www.ilsl.br Location: BR191.1

---

page 1 de 1

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information